share_log

Adial Pharmaceuticals | D: Filing D

Adial Pharmaceuticals | D: Filing D

Adial Pharmaceuticals | D：發行公告
美股SEC公告 ·  03/14 17:16

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals, Inc., a biopharmaceutical company based in Glen Allen, Virginia, has filed a Form D Notice of Exempt Offering of Securities with the Securities and Exchange Commission (SEC). The filing, dated March 14, 2024, indicates that the company has successfully raised $287,500 through an equity offering. The offering, which includes options, warrants, or other rights to acquire another security, was made under Rule 506(b) of the Securities Act, exempting it from registration requirements. The first sale of the securities occurred on March 6, 2024, and the offering is not intended to last more than one year. Adial Pharmaceuticals has declined to disclose the issuer size by revenue or aggregate net asset value. The company has also stated that none of the proceeds from the...Show More
Adial Pharmaceuticals, Inc., a biopharmaceutical company based in Glen Allen, Virginia, has filed a Form D Notice of Exempt Offering of Securities with the Securities and Exchange Commission (SEC). The filing, dated March 14, 2024, indicates that the company has successfully raised $287,500 through an equity offering. The offering, which includes options, warrants, or other rights to acquire another security, was made under Rule 506(b) of the Securities Act, exempting it from registration requirements. The first sale of the securities occurred on March 6, 2024, and the offering is not intended to last more than one year. Adial Pharmaceuticals has declined to disclose the issuer size by revenue or aggregate net asset value. The company has also stated that none of the proceeds from the offering will be used to make payments to its executive officers, directors, or promoters. The sole investor in the offering is not an accredited investor, and sales commissions of $23,000 were estimated to be paid to H.C. Wainwright & Co., LLC. The company specializes in the pharmaceuticals sector within the healthcare industry and is incorporated in Delaware.
總部位於弗吉尼亞州格倫艾倫的生物製藥公司Adial Pharmicals, Inc. 已向美國證券交易委員會（SEC）提交了D表豁免證券發行通知。這份日期爲2024年3月14日的文件顯示，該公司已通過股票發行成功籌集了287,500美元。此次發行包括期權、認股權證或其他收購其他證券的權利，是根據《證券法》第506（b）條進行的，免除了註冊要求。證券的首次出售發生在2024年3月6日，本次發行的持續時間不超過一年。Adial Pharmicals拒絕按收入或總淨資產價值披露發行人規模。該公司還表示，此次發行的收益均不會用於向其執行官、董事或發起人付款。此次發行的唯一投資者不是合格投資者，估計將向H.C. Wainwright & Co., LLC支付23,000美元的銷售佣金。該公司專門從事醫療保健行業的製藥行業，並在特拉華州註冊成立。
總部位於弗吉尼亞州格倫艾倫的生物製藥公司Adial Pharmicals, Inc. 已向美國證券交易委員會（SEC）提交了D表豁免證券發行通知。這份日期爲2024年3月14日的文件顯示，該公司已通過股票發行成功籌集了287,500美元。此次發行包括期權、認股權證或其他收購其他證券的權利，是根據《證券法》第506（b）條進行的，免除了註冊要求。證券的首次出售發生在2024年3月6日，本次發行的持續時間不超過一年。Adial Pharmicals拒絕按收入或總淨資產價值披露發行人規模。該公司還表示，此次發行的收益均不會用於向其執行官、董事或發起人付款。此次發行的唯一投資者不是合格投資者，估計將向H.C. Wainwright & Co., LLC支付23,000美元的銷售佣金。該公司專門從事醫療保健行業的製藥行業，並在特拉華州註冊成立。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間